New Development in CAR-T Cell Therapy

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2017 Feb 23

PMID 28222796

Citations 183

Authors

Zhenguang Wang

Zhiqiang Wu

Yang Liu

Weidong Han

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor antigen escape has emerged as a main challenge for the long-term disease control of this promising immunotherapy in B cell malignancies. In addition, this success has encountered significant hurdles in translation to solid tumors, and the safety of the on-target/off-tumor recognition of normal tissues is one of the main reasons. In this mini-review, we characterize some of the mechanisms for antigen loss relapse and new strategies to address this issue. In addition, we discuss some novel CAR designs that are being considered to enhance the safety of CAR-T cell therapy in solid tumors.

Citing Articles

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade.

Li J, Luo Y, Fu Q, Tang S, Zhang P, Frazer I Sci Rep. 2025; 15(1):3789.

PMID: 39885296 PMC: 11782643. DOI: 10.1038/s41598-025-87687-0.

Modular (universal) CAR-T platforms : a comprehensive systematic review.

Mohammad A, Yurina A, Simonyan T, Chistyakov D, Salman R, Zornikova K Front Immunol. 2024; 15:1409665.

PMID: 39712013 PMC: 11659234. DOI: 10.3389/fimmu.2024.1409665.

Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptor-like specificity.

Haus-Cohen M, Reiter Y Front Immunol. 2024; 15():1486721.

PMID: 39650646 PMC: 11621052. DOI: 10.3389/fimmu.2024.1486721.

Epigenetics behind CD8 T cell activation and exhaustion.

Zu H, Chen X Genes Immun. 2024; 25(6):525-540.

PMID: 39543311 DOI: 10.1038/s41435-024-00307-1.

SPI1CD68 macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies.

Deng G, Wang P, Su R, Sun X, Wu Z, Huang Z J Immunother Cancer. 2024; 12(10).

PMID: 39455096 PMC: 11529461. DOI: 10.1136/jitc-2024-009983.

References

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

Ribas A, Timmerman J, Butterfield L, Economou J . Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003; 24(2):58-61. DOI: 10.1016/s1471-4906(02)00029-7. View

Chmielewski M, Hombach A, Heuser C, Adams G, Abken H . T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004; 173(12):7647-53. DOI: 10.4049/jimmunol.173.12.7647. View

Noy R, Eppel M, Haus-Cohen M, Klechevsky E, Mekler O, Michaeli Y . T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy. Expert Rev Anticancer Ther. 2005; 5(3):523-36. DOI: 10.1586/14737140.5.3.523. View

Eshhar Z . The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol. 2007; (181):329-42. DOI: 10.1007/978-3-540-73259-4_14. View

Li G, Wong A . EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev Vaccines. 2008; 7(7):977-85. DOI: 10.1586/14760584.7.7.977. View

Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-51. PMC: 2862534. DOI: 10.1038/mt.2010.24. View

Hermann P, Bhaskar S, Cioffi M, Heeschen C . Cancer stem cells in solid tumors. Semin Cancer Biol. 2010; 20(2):77-84. DOI: 10.1016/j.semcancer.2010.03.004. View

Zhao Y, Moon E, Carpenito C, Paulos C, Liu X, Brennan A . Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010; 70(22):9053-61. PMC: 2982929. DOI: 10.1158/0008-5472.CAN-10-2880. View

10.

Wang X, Chang W, Wong C, Colcher D, Sherman M, Ostberg J . A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011; 118(5):1255-63. PMC: 3152493. DOI: 10.1182/blood-2011-02-337360. View

11.

Kalos M, Levine B, Porter D, Katz S, Grupp S, Bagg A . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95):95ra73. PMC: 3393096. DOI: 10.1126/scitranslmed.3002842. View

12.

Barrett D, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M . Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther. 2011; 22(12):1575-86. PMC: 3237694. DOI: 10.1089/hum.2011.070. View

13.

Di Stasi A, Tey S, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C . Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011; 365(18):1673-83. PMC: 3236370. DOI: 10.1056/NEJMoa1106152. View

14.

Curran K, Pegram H, Brentjens R . Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. 2012; 14(6):405-15. PMC: 4697438. DOI: 10.1002/jgm.2604. View

15.

Dahan R, Reiter Y . T-cell-receptor-like antibodies - generation, function and applications. Expert Rev Mol Med. 2012; 14:e6. DOI: 10.1017/erm.2012.2. View

16.

Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J . Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012; 72(7):1853-64. PMC: 3320735. DOI: 10.1158/0008-5472.CAN-11-1400. View

17.

Wilkie S, van Schalkwyk M, Hobbs S, Davies D, van der Stegen S, Parente Pereira A . Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012; 32(5):1059-70. DOI: 10.1007/s10875-012-9689-9. View

18.

Erster O, Thomas J, Hamzah J, Jabaiah A, Getz J, Schoep T . Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release. 2012; 161(3):804-12. PMC: 3412904. DOI: 10.1016/j.jconrel.2012.05.035. View

19.

Kloss C, Condomines M, Cartellieri M, Bachmann M, Sadelain M . Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2012; 31(1):71-5. PMC: 5505184. DOI: 10.1038/nbt.2459. View

20.

Hanada K, Restifo N . Double or nothing on cancer immunotherapy. Nat Biotechnol. 2013; 31(1):33-4. PMC: 6352981. DOI: 10.1038/nbt.2471. View